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MMP-12 is a member of matrix metalloproteinases (MMPs) family involved in pathogenesis of some inflammatory based diseases.
Design of selectivematrixMMPs inhibitors is still challenging because of binding pocket similarities amongMMPs family.We tried
to generate a HQSAR (hologram quantitative structure activity relationship) model for a series of MMP-12 inhibitors. Compounds
in the series of inhibitors with reported biological activity against MMP-12 were used to construct a predictive HQSAR model for
their inhibitory activity against MMP-12. The HQSAR model had statistically excellent properties and possessed good predictive
ability for test set compounds. The HQSAR model was obtained for the 26 training set compounds showing cross-validated 𝑞2
value of 0.697 and conventional 𝑟2 value of 0.986. The model was then externally validated using a test set of 9 compounds and the
predicted values were in good agreement with the experimental results (𝑟2pred = 0.8733).Then, the external validity of themodel was
confirmed by Golbraikh-Tropsha and 𝑟2
𝑚
metrics. The color code analysis based on the obtained HQSAR model provided useful
insights into the structural features of the training set for their bioactivity against MMP-12 and was useful for the design of some
new not yet synthesized MMP-12 inhibitors.
1. Introduction
Matrix metalloproteinases (MMPs) family enzymes can
degrade extracellular matrix components by their proteolytic
activity which depends on catalytic zinc ion [1].Themain role
of macrophage metalloelastase (MMP-12) is degradation of
elastin. Furthermore, MMP-12 is an interesting therapeutic
target overexpressed in inflammatory pathological condi-
tions (such as respiratory system diseases including asthma
and chronic obstructive pulmonary disorder (COPD)) [2].
Effectiveness ofMMP-12 inhibitors in reducing inflammation
in respiratory system has been shown [3, 4].
The active site is highly conserved amongMMPs with the
exception of a loop region called S1󸀠. S1󸀠 pocket in MMPs
active sites varies slightly among MMPs in both sequence
and structure [5]. Despite available structural information,
still the lack of selectivity remains as a main challenge for
successfulness of MMPs inhibitors in clinical trials. Further-
more, intrinsic flexibility of MMPs active sites makes MMPs
active site analysis more complicated [6, 7]. Therefore, in this
study, a ligand based approach was used to modify the side
chain in a series of MMP-12 inhibitors. HQSAR (hologram
quantitative structure activity relationship) is a method for
QSAR (quantitative structure activity relationship) studies
whose reliability has been established [8]. In the present
study, a HQSAR study on a series of tricycle cores containing
MMP-12 inhibitors was carried out.
2. Methods
2.1. Obtaining Biological Data and Generation of Molecular
Structures. The structures of 35 MMP-12 inhibitors and their
biological activities for inhibition of MMP-12 were taken
from the literatures (Figure 1 and Table 1) [9, 10]. As the
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Table 1: Actual and predicted activities of the training and test sets based on the HQSAR model. Activities were shown as pIC50 (𝜇M).
Name R Actual pIC50 values Predicted pIC50 values Residues
Normalized mean
distance score
10
O
O
N
2.699 2.594 0.105 0.066
11
N
N N 1.8861 2.05 −0.1639 0.028
12 N
N
1.8239 2.144 −0.3201 0.022
13
N
N
CF3
3.1549 2.688 0.4669 0.049
14 N NH 1.6383 1.646 −0.0077 0.332
15a N N 1.7447 1.754 −0.0093 0.065
16 N O 2.6576 2.672 −0.0144 0.208
19
O
3.3979 3.706 −0.3081 0.037
20
O
4 4.032 −0.032 0.043
21
O
Cl
4 3.778 0.222 0.03
22
S
3.699 3.647 0.052 0.033
23
S
3.699 3.752 −0.053 0.031
24
N
NH 3 3.049 −0.049 0.005
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Table 1: Continued.
Name R Actual pIC50 values Predicted pIC50 values Residues
Normalized mean
distance score
25a
N
H
3.3979 3.17 0.2279 0.085
26
N
S
3 2.945 0.055 0.009
27
N
S
2.9208 2.949 −0.0282 0.008
33 Methyl 2.0655 2.341 −0.2755 0
34 Ethyl 2.5376 2.452 0.0856 0.01
35 i-Propyl 2.3468 2.423 −0.0762 0.087
36 t-Butyl 1.7696 1.839 −0.0694 0.554
37 i-Butyl 2.2676 2.203 0.0646 0.284
38 CH2OCH3 2.7212 2.571 0.1502 0.007
39 CF3 2.6576 2.543 0.1146 0
40 Cyclopropyl 2.7959 2.767 0.0289 0.08
41 Cyclobutyl 2.6383 2.689 −0.0507 0.377
42 Cyclohexyl 2.1427 2.126 0.0167 1
43 Phenyl 2.3979 2.561 −0.1631 0.116
44 O 3.5229 3.491 0.0319 0.186
51a
O
O
NH
2.5441 2.483 0.0611 0.059
52a
O
O
NH 2.0969 2.502 −0.4051 0.088
53a O
O
NH
2.173 2.146 0.027 0.297
54a
O
O
NH
F
2.5229 2.526 −0.0031 0.049
55a
O
O
NH H
N 2.1461 2.305 −0.1589 0.324
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Table 1: Continued.
Name R Actual pIC50 values Predicted pIC50 values Residues
Normalized mean
distance score
56a O
O
NH H
N
S
2.8909 2.616 0.2749
57a
O
O
NH H
N
S
2.8037 2.773 0.0307 0.668
aTest set compounds.
HO
O
O
O
O
NH
S
R
Figure 1: General structure for dataset.
activity of compound 10 is determined in both studies,
we normalized the IC
50
based on the reported activity for
compound 10. The range of pIC
50
(𝜇M) values for MMP-12
spans around three orders ofmagnitude (min = 1.6383, max =
4) in training set.The compounds were divided into two sets,
training (𝑛 = 26) and test (𝑛 = 9) sets, according to the main-
taining of structural diversity and the uniform distribution
of IC
50
. The pIC
50
(−Log IC
50
) was employed as dependent
variable instead of IC
50
. The molecular structures were
built using PyMOL (http://www.pymol.org/, The PyMOL
Molecular Graphics System, Version 1.2r3pre, Schro¨dinger,
LLC). The HQSAR model was developed by SYBYL-X1.2
molecularmodeling package (Tripos International, St. Louis).
2.2. HQSAR Model Generation and Validation. HQSAR
technique explores the contribution of each fragment of
each molecule under study to the biological activity. As
inputs, it needs datasets with their corresponding inhibitory
activity in terms of pIC
50
. Structures in the dataset were
fragmented and hashed into array bins. Molecular hologram
fingerprints were then generated. Hologram was constructed
by cutting the fingerprint into strings at various hologram
length parameters.
After generation of descriptors, partial least square (PLS)
methodology was used to find the possible correlation
between dependent variable (−pIC
50
) and independent vari-
able (descriptors generated by HQSAR structural features).
LOO (leave-one-out) cross-validation method was used to
determine the predictive value of the model. Optimum num-
ber of components was found out using results from LOO
calculations. At this step, 𝑞2 and standard error obtained from
leave-one-out cross-validation roughly estimate the predic-
tive ability of the model. This cross-validated analysis was
followed by a non-cross-validated analysis with the calculated
optimum number of principle components. Conventional
correlation coefficient 𝑟2 and standard error of estimate (SEE)
indicated the validity of themodel.The internal validity of the
model was also tested by 𝑌-randomization method [11]. In
this test, the dependent variables are randomly shuffled while
the independent variables (descriptors) are kept unchanged.
It is expected that 𝑞2 and 𝑟2 calculated for these random
datasets will be low. Finally, a set of compounds (which were
not present in model development process) with available
observed activity were used for external validation of the
generated model. Predictive 𝑟2 (𝑟2pred) value was calculated
using
𝑟
2
pred = 1 −
PRESS
SD
; (1)
PRESS: sum of the squared deviation between pre-
dicted and actual pIC
50
for the test set compounds;
SD: sum of the squared deviation between the actual
pIC
50
values of the compounds from the test set and
the mean pIC
50
value of the training set compounds.
The external validity of the model was also evaluated by
Golbraikh-Tropsha [12] method and 𝑟2
𝑚
[13] metrics. For an
acceptable QSAR model, the value of “average 𝑟2
𝑚
” should
be >0.5 and “delta 𝑟2
𝑚
” should be <0.2. The applicability
domain of the generated model was evaluated for both test
and prediction sets by Euclidean based method. It calculates
a normalized mean distance score for each compound in
training set in range of 0 (least diverse) to 1 (most diverse).
Then, it calculates the normalized mean distance score for
compounds in an external set. If a score is outside the 0
to 1 range, it will be considered outside of the applicability
domain. The external validity tests (Golbraikh-Tropsha and
Rm2) and applicability domain test were done using tools
available at http://dtclab.webs.com/software-tools.
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Figure 2: Plot of observed versus predicted activity obtained from
HQSAR model for training and test sets.
2.3. Prediction Set (Design of New Compounds). The predic-
tion set contained 5 new not yet synthesized compounds
having unknown observed values of activity against MMP-
12. They were designed based on the prediction ability of
developed HQSAR model.
2.4. Molecular Docking. The molecular docking process was
carried out employing Glide (Glide, version 5.7, Schro¨dinger,
LLC, New York, NY, 2011) using default parameters. The
protein (3F17) was prepared using Protein Preparation Wiz-
ard. Hydrogens were added, bond orders were assigned,
overlapping hydrogens were corrected, missing side chains
were added, and water molecules were removed. Finally,
the protein structure was minimized by OPLS2005 force
field. The prepared protein structure containing inhibitor
molecule was used for active site definition (within 13A
from cocrystalized ligand). The 2D maps of ligands-receptor
interactions were generated by ligand interaction diagram
(Schro¨dinger molecular modeling suite).
3. Results
3.1. HQSAR Model Predictivity. The statistics for developed
HQSAR model were shown in Table 2. The statistical param-
eters, 𝑞2, 𝑟2, SEE, and 𝑟2pred, showed the validity of our model.
The best hologram model was generated using histogram
length of 199 having six optimum components. Descrip-
tors used for model generation were atoms, connections,
and hydrogen atoms. The best generated model had cross-
validated 𝑞2 of 0.697 and non-cross-validated 𝑟2 value of
0.986 with a standard error of 0.93.The total collection of the
generated models for various histogram lengths comprises
ensemble, and the ensemble value for 𝑟2 was found to
be 0.528. The 𝑌-randomization results indicated that the
calculated 𝑞2 (−1.238, −0.303, −0.793, 0.081, and −0.146) and
𝑟
2 (0.683, 0.088, 0.086, 0.241, and 0.126) for five random
models are very low which also confirm the internal validity
of the generated HQSAR model. The results of 𝑟2pred calcula-
tion showed that the proposed HQSAR model was reliable
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Figure 3: Contribution plot obtained from hologram quantitative
structure activity relationship model for (a) compound 19 and (b)
compound 20.
and could successfully predict pIC
50
for structurally related
compounds which were not included in development of the
models. The 𝑟2
𝑚
(after scaling) was 0.825 and delta 𝑟2
𝑚
was
0.107. Additionally, all four conditions of The Golbraikh-
Tropsha method are satisfied (𝑟2 = 0.876). Predicted
values for the activity of molecules are shown in Table 1 and
the experimental pIC
50
against the values predicted by the
HQSAR models are plotted (Figure 2).
3.2. HQSAR Atomic Contribution Plot. The generated model
can be accessed through atomic contribution plot. The vari-
ous colors of each atom correspond to various degrees of con-
tribution towards the overall biological activity. Red, red
orange, and orange depicted that the color belonging atoms
were contributing negatively to the generated HQSARmodel
while colors reflecting yellow, green, and green blue were
contributing positively to the model. Intermediate contribu-
tions were reflected by gray atom. The maximum common
substructure was shown in cyan. Figure 3 depicts the contri-
bution of the most potent compound 20 as well as compound
19.
3.3. Prediction Set (Design of New Virtual Compounds). This
work allowed prediction of the activity of a set shown in
Table 3 (not yet synthesized molecules). Their inhibitory
activities were calculated according to the HQSAR model.
They were designed based on compound 19 (one of the
most active compounds). We had proposed a set of 5 new
structures; some of them may show improved experimental
MMP-12 inhibitory activity in comparison with the parent
compound. This hypothesis and their selectivity should be
verified experimentally.
3.4. Molecular Docking. The molecular docking approach
was employed to further analyze the ability of designed
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Figure 4: 2D interaction diagram of 3 docked designed compounds: (a) structure 26, (b) structure 20, and (c) structure n3.
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Figure 5: Compound 20 in the active site of MMP-12 (docked by
Glide).
Table 2: Statistical characteristics of the developed HQSAR model.
Parameter Value
Number of compounds included in training set 26
Optimum number of components used in the PLS
analysis 6
𝑞
2 (cross-validated correlation coefficient) 0.697
SEEa (𝑞2) 0.428
𝑟
2 (non-cross-validated correlation coefficient) 0.986
SEE (𝑟2) 0.093
𝑟
2 (ensembleb) 0.528
SEE (ensemble) 0.530
Best hologram length 199
Used information
Atoms
+ Connections
+ Hydrogen
atoms
𝑟
2
pred 0.8733
aSEE: standard error of estimate. bFor each hologram length, a model could
be established. The collection of these models comprises the ensemble.
compounds in inhibition of MMP-12. In Table 3, the docking
scores of the 3 new designed compounds and 3 molecules
from train set were reported.The binding positions of all new
compounds were inspected for their binding conformation
and interactions inMMP-12 active site. For n3, 2D diagram of
ligand-receptor interaction was presented (Figure 4(c)). The
various heterocyclic rings substituted on the dibenzofuran
scaffold do not seem to have strong interactions with the
binding pocket of MMP-12 as it was suggested previously by
X-ray crystallography [9]. However, if they have undesired
properties they cannot fit in the narrow deep S1󸀠 pocket
of MMP-12. On the other hand, they can induce steric
hindrance that prevents other parts of the molecule to have
strong interactions with residues in the binding pocket. The
conformation of the heterocyclic ring upon ligand binding is
demonstrated in Figure 5.
4. Discussion
We successfully developed a HQSAR model for prediction
of some MMP-12 inhibitors with good internal and external
validity. Subsequently, the model was used to predict the
activity of newMMP-12 inhibitors.Thebinding energy of new
not yet synthesized molecules was evaluated by molecular
docking.
Crystal structures have provided useful information
for developing selective inhibitors toward particular MMPs
including MMP-12. The segment 241–245 of MMPs (MMP-1
numbering) has the highest sequence variability among the
various MMP enzymes and could be a target for designing
selective inhibitors. However, this segment is very flexible
which makes the molecular modeling predictions using 3D
structures of MMPs inaccurate [14, 15]. Only some small dif-
ferences in the sizes of hydrophobic side chainswere seen. For
example, Val 235 inMMP-12 is replaced by Leu214 inMMP-13
which makes the MMP-13 binding pocket smaller and more
hydrophobic. The series of MMP-12 inhibitors employed in
this study had carboxylic acid zinc binding group. Changing
the R group that was placed in hydrophobic pocket of MMP-
12 active site altered the potency and selectivity of these
inhibitors. We modified this R group for fine tuning and
designed new compound with promisingMMP-12 inhibitory
activity.
In the present study, we used HQSAR approach for a set
of MMP-12 inhibitors. Contribution plot (Figure 3) showed
that the green aromatic carbon was contributing positively
to the model. Oxygen atom in furan ring was depicted
by green or yellow and was contributing to the biological
activity. Hydrogen molecules were rendered green, yellow, or
white indicating that they showed intermediate contribution.
The bulky group (methyl) was green indicating that it was
contributing positively to the generated model, and it can be
explained from the example that compound 20 was showing
high potency. The developed model was used for the design
of 5 new molecules. Overall docked conformation of the
training set of inhibitors and new compounds in MMP-12
active site was similar to one determined by crystallography.
Among new designed compounds, compounds n1, n2, and n3
had low SEP and their predicted activities were more reliable.
Furthermore, compound n3 has the lowest docked energy.
5. Conclusion
In summary, we have developed a reliable HQSARmodel for
a series of tricycle cores containing MMP-12 inhibitors with
dibenzofuran ring using activity data reported earlier [9, 10].
We used HQSAR analysis to design new not yet synthesized
potent MMP-12 inhibitors. Their binding energies were eval-
uated by docking studies but for further validation it needs
synthesize of the proposed new compounds and subsequent
enzyme inhibition study.
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Table 3: Predicted activities for the molecules based on the HQSAR model. Activities were shown as pIC50 (𝜇M).
Name R PredictedpIC50 values
SE of prediction Normalized meandistance score Docking score
n1 O 4.182 0.158579 0.161 −12.038972
n2
O
3.89 0.097741 0.076 −13.92
n3
O
3.942 0.093502 0.072 −13.87
n4
O
3.846 0.308627 0.291 —a
n5 O 4.003 0.325568 0.315 —a
20 (observed = 4)
O
4.032 — 0.043 −13.7908
19 (observed = 3.3979)
O
3.706 — 0.037 −12.555956
26 (observed = 3)
N
O
2.945 — 0.009 −11.781243
aDocking was not performed for these compounds.
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